You have 9 free searches left this month | for more free features.

fludarabine

Showing 26 - 50 of 741

STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS

Non Hodgkin's Lymphoma Trial in Beijing (TRAC and Power3 Genes Knock-out Allogeneic CD19-targeting CAR-T cell (ATHENA CAR-T),

Not yet recruiting
  • Non Hodgkin's Lymphoma
  • TRAC and Power3 Genes Knock-out Allogeneic CD19-targeting CAR-T cell (ATHENA CAR-T)
  • +2 more
  • Beijing, China
  • +2 more
Aug 23, 2023

Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Biphenotypic Acute Leukemia Trial in Tampa (Fludarabine, Melphalan, Total

Active, not recruiting
  • Acute Myeloid Leukemia
  • +17 more
  • Fludarabine
  • +2 more
  • Tampa, Florida
    H. Lee Moffitt Cancer Center & Research Institute
Jan 10, 2023

Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Trial in Nanjin (Orelabrutinib, Obinutuzumab, Fludarabine)

Recruiting
  • Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
  • Nanjin, Jiangsu, China
    Department of Haematology, the First Affiliated Hospital of Nanj
Apr 12, 2022

Non Hodgkin Lymphoma Trial in Cleveland (UF-KURE19 CAR-T cells, Fludarabine, Cyclophosphamide)

Recruiting
  • Non Hodgkin Lymphoma
  • UF-KURE19 CAR-T cells
  • +2 more
  • Cleveland, Ohio
  • +1 more
Nov 21, 2022

Hematologic Malignancies Trial in New York (Busulfan 3.2 mg/kg/day, Fludarabine, Melphalan)

Recruiting
  • Hematologic Malignancies
  • Busulfan 3.2 mg/kg/day
  • +5 more
  • New York, New York
    Memorial Sloan Kettering Cancer Center
Mar 14, 2022

Non-hodgkin Lymphoma,B Cell Trial in Beijing (Autologous CD19-STAR-T cell, Fludarabine, Cyclophosphamide)

Recruiting
  • Non-hodgkin Lymphoma,B Cell
  • Autologous CD19-STAR-T cell
  • +2 more
  • Beijing, Beijing, China
  • +1 more
Nov 21, 2022

Fludarabine Drug Exposure in Pediatric Bone Marrow

Completed
  • Hematologic Malignancies
  • +7 more
  • Fludarabine
  • San Francisco, California
    University of California, San Francisco
Sep 27, 2021

Chronic Lymphocytic Leukemia Trial in Boston (IPI-145, Fludarabine, Cyclophosphamide)

Active, not recruiting
  • Chronic Lymphocytic Leukemia
  • Boston, Massachusetts
  • +1 more
Mar 10, 2022

Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia Trial in Houston (procedure, drug, biological)

Recruiting
  • Recurrent Acute Myeloid Leukemia
  • Refractory Acute Myeloid Leukemia
  • Allogeneic Hematopoietic Stem Cell Transplantation
  • +7 more
  • Houston, Texas
    M D Anderson Cancer Center
Aug 18, 2022

B-Lymphoid Malignancies, Acute Lymphocytic Leukemia, Chronic Lymphocytic Leukemia Trial in Houston (Fludarabine,

Active, not recruiting
  • B-Lymphoid Malignancies
  • +3 more
  • Fludarabine
  • +4 more
  • Houston, Texas
    University of Texas MD Anderson Cancer Center
Aug 1, 2022

Leukemia, Juvenile Myelomonocytic, JMML, JCML Trial (Trametinib, Azacitidine, Fludarabine)

Not yet recruiting
  • Leukemia, Juvenile Myelomonocytic
  • +4 more
  • (no location specified)
May 4, 2023

Relapsed/Refractory B-Cell Lymphoma Trial (FT522, Rituximab, Cyclophosphamide)

Not yet recruiting
  • Relapsed/Refractory B-Cell Lymphoma
  • (no location specified)
Jul 10, 2023

Relapsed/Refractory Large B-cell Lymphoma Trial (KITE-197, Cyclophosphamide, Fludarabine)

Not yet recruiting
  • Relapsed/Refractory Large B-cell Lymphoma
  • (no location specified)
Oct 6, 2023

Hematologic Malignancies Trial in Chicago, New York (device, drug, radiation)

Recruiting
  • Hematologic Malignancies
  • CliniMACS® CD34 Reagent System
  • +7 more
  • Chicago, Illinois
  • +1 more
Sep 20, 2022

Chronic Lymphocytic Leukemia, Leukemia Trial in United States (Ibrutinib, Fludarabine, Cyclophosphamide)

Active, not recruiting
  • Chronic Lymphocytic Leukemia
  • Leukemia
  • Coral Gables, Florida
  • +8 more
Sep 28, 2022

Acute Lymphoblastic Leukemia, Acute Lymphoblastic Leukemia in Remission, Acute Myeloid Leukemia Trial in Duarte (drug, other,

Recruiting
  • Acute Lymphoblastic Leukemia
  • +7 more
  • Fludarabine
  • +3 more
  • Duarte, California
    City of Hope Medical Center
Feb 17, 2022

Cutaneous T-cell Lymphoma, T-Prolymphocytic Leukemia, T-Large Granulocytic Leukemia Trial in Columbus (Romidepsin, Busulfan,

Recruiting
  • Cutaneous T-cell Lymphoma
  • +4 more
  • Columbus, Ohio
    The Ohio State University Cancer Center
Apr 18, 2022

Acute Myeloid Leukaemia Trial (SAR445419, fludarabine, cytarabine)

Not yet recruiting
  • Acute Myeloid Leukaemia
  • (no location specified)
Feb 2, 2023

Acute Myelogenous Leukemia, MDS, Mixed Phenotype Acute Leukemia Trial (Fludarabine, Cytarabine, Uproleselan)

Not yet recruiting
  • Acute Myelogenous Leukemia
  • +2 more
  • Fludarabine
  • +2 more
  • (no location specified)
Mar 3, 2022

Sickle Cell Disease Trial in Hackensack (Alemtuzumab, Fludarabine, Melphalan)

Active, not recruiting
  • Sickle Cell Disease
  • Hackensack, New Jersey
    Hackensack University Medical Center
Feb 4, 2022

Myeloid Hematological Malignancies Trial in Houston (Busulfan, Cyclophosphamide, Fludarabine)

Completed
  • Myeloid Hematological Malignancies
  • Houston, Texas
    Texas Children's Hospital
May 13, 2022

Relapsed and/or Refractory Multiple Myeloma Trial in Köln (BMS-986453, Fludarabine, Cyclophosphamide)

Not yet recruiting
  • Relapsed and/or Refractory Multiple Myeloma
  • Köln, Germany
    Local Institution - 0017
Dec 4, 2023

CD19-positive Relapsed or Refractory B-cell Malignancies Trial in Hefei (UTAA09 cells for infusion, Fludarabine,

Not yet recruiting
  • CD19-positive Relapsed or Refractory B-cell Malignancies
  • UTAA09 cells for infusion
  • +2 more
  • Hefei, Anhui, China
    The First Affiliated Hospital of USTC (AnHui Provincial Hospital
Oct 13, 2023

Solid Tumor Trial (Tumor Infiltrating Lymphocytes, Fludarabine, Cyclophosphamide Capsules)

Not yet recruiting
  • Solid Tumor
  • Tumor Infiltrating Lymphocytes
  • +3 more
  • (no location specified)
Dec 11, 2022

Hepatocellular Carcinoma, Hepatocellular Cancer, Metastatic Hepatocellular Carcinoma Trial run by the NCI (Cyclophosphamide,

Recruiting
  • Hepatocellular Carcinoma
  • +2 more
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
Jan 20, 2023